2024-520212-18-00CompletedPhase 1
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 21 Feb 2025
- Start date
- 3 Apr 2025
- Lead sponsor
- Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
- EU CT number
- 2024-520212-18-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cepha s.r.o. | Plzen 1 | Czechia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.